Information for Applicants and terms and conditions of funding
Please find all the information below needed to guide you in completing your application, as well as the specific criteria for assessment and conditions of funding.
The following process has been prepared by Cure Brain Cancer Foundation using reasonable endeavours but it is subject to change at any time.
1. General Information
1.1 Opening and closing dates for applications are specified below and on Cure Brain Cancer’s Current Funding Opportunities webpage. Late applications will not be accepted.
1.2 All information, required documents and application forms for funding are available on Cure Brain Cancer Foundation’s online grant portal, website, or by contacting the Cure Brain Cancer Foundation Research Administration Office.
1.3 Full applications must be submitted through the Cure Brain Cancer Foundation online grant portal. Grants will not be considered if submitted via other channels. All questions should be answered correctly and honestly.
1.4 For each program, only one grant can be submitted per Principal Investigator. The Principal Investigator can be co-investigator on multiple grants.
1.5 Cure Brain Cancer Foundation will not fund equipment.
funding decisions made by Cure Brain Cancer Foundation are final. Appeals will
not be considered and feedback will not be provided to applicants.
If you have any general concerns with the terms of funding please let us know.
2. Criteria for Assessing Applications
The following criteria will be used to rank applications and to decide which will be offered Cure Brain Cancer Foundation funding.
Key Evaluation Criteria
2.1 Applicant capability:
Do the key personnel have the expertise, experience and ability to undertake the proposed project and meet milestones and timelines?
2.2 Novelty of the project. Novelty of concept, originality and innovation:
Does the proposed project have elements of its design, approach or concept that are novel and have the potential to asnswer or discover new information and/or potential to advance scientific knowledge and/or clinical practice?
2.3 Impact. Potential to improve brain cancer survival:
Will this project contribute to increasing brain cancer survival rates within 10 years?
2.4 Quality and feasability. Scientific quality and feasibility of proposed project and/or rationale:
For all research projects, the following will be assessed; Is the study rationale based on previous well-designed
research? Is the study design adequate to answer the proposed research
questions and test the hypotheses? Are ethical issues sufficiently addressed?
Is the proposed timeline feasible? Does the proposal address plans to obtain
any required study agents? Is the proposed analysis and statistical approach
appropriate to provide interpretable results from the proposed study design and
methods? Do the clinical site(s) or laboratories have adequate procedures for
data management and quality control? Does the proposal address quality control
methods for the standardisation of data management, to adequately assess the
effect of the intervention? Does the proposal adequately address the capacity
and capability of the proposed site(s) or centres to conduct the planned
If the proposal is a clinical trial, the following will also
Does the proposal provide adequate justification
for the study populations, proposed intervention arms/dose and duration of the
trial? In terms of recruitment, are there plans for outreach, enrolment,
retention, handling dropouts, missed visits and losses? Is the eligible
population available for the proposed study? Have inclusion/ exclusion criteria
Is the budget appropriate for the study?
Grant Specific Evaluation Criteria
2.6 Collaborative effort and mentorship. Collaboration with external research groups in Australia:
Have the key personnel demonstrated collaborative effort and mentorship with external research groups in Australia?
2.7: Building capacity in brain cancer research. To what extent will this group help to build capacity in brain cancer research in Australia?
To what extent will this group help to build capacity in brain cancer research in Australia? Does the proposed project adequately address the need for infrastructure in Australia?
3. Expected Outcomes for Cure Brain Cancer Foundation
Funding will be provided to investigators with a strong track record in cancer research and strong institutional support that submit applications with the greatest potential to achieve the outcomes it seeks from its research funding.
Increase 5 year survival to 50% in 10 years
Accelerating treatments to patients
- Research of high scientific merit
- Research employing the best technology available for the problem under investigation
- Research at a cost that is commensurate with the results to be achieved
- Research concerned with brain cancer that have a high impact on brain cancer incidence, morbidity or mortality
- Research addressing issues identified as a critical concern by the brain cancer community
- Research concerned with filling gaps in knowledge and understanding judged in brain cancer
- Translation of research results into the practice of early detection or clinical care
- Development of patents and commercial products
- Contribution to knowledge as measured by publications and, subsequently, citations
- Direct contribution to public policy relating to cancer control.
- Increased numbers and quality of investigators committed to brain cancer research in Australia
- The attraction of additional research funding from other funding sources as a result of the Foundation’s investment
- Improvements in research technology, productivity or quality
- Enhancements in the competitiveness of Australian brain cancer research
- The development of durable research partnerships, networks or collaborations
4. Format for Applications
4.1 All applicants should complete the Online Application Form, available through Cure Brain Cancer Foundation’s grant portal.
4.2 Clearly address the Selection Criteria in Section 2 above.
5. Timelines for Assessment
Outlined below is the timeline for grants to be funded in 2018:
7 February 2018: Infrastructure grants open.
7 March 2018: Innovation grant expression of interest open.
19 March 2018: Infrastructure grants close.
20 April 2018: Innovation grant expressions of interes close.
9 May 2018: Immunotherapy trial grant opens.
31 May 2018: Innovation grant round 2 open.
20 June 2018: Immunotherapy trial grant closes.
29 June 2018: Innovation grant round 2 closes.
6. Eligible Applicants
6.1 Research groups working in Australian institutions are eligible to apply.
6.2 The formation of multidisciplinary and multi-institutional consortia is encouraged. Collaborative projects with co-workers outside Australia will be subject to the condition that funds may only be used to meet costs incurred in Australia, or the purchase of products or services that are directly related to the Australian component of a collaborative project.
6.3 Any additional award-specific eligibility criteria will apply as listed on the Current Funding Opportunities page of CBCF’s website.
7.1 The assessment of applications for grants will include at least the following steps:
- Review of all grants by the Scientific Advisory Committee.
- Interview of selected applicants by Scientific Advisory Committee
- Recommendation from the Scientific Advisory Committee regarding which applications justify support and their ranked order
- Recommendation from the Scientific Advisory Committee to the Cure Brain Cancer Foundation Board of the applications that should be offered support and at what levels.
OTHER CONDITIONS OF FUNDING
8.1 The following process has been prepared by Cure Brain Cancer Foundation using reasonable endeavours but it is subject to change at any time.
8.2 Submission of any applications do not purport to be a contract with Cure Brain Cancer Foundation.
8.3 Grant funding is for a maximum of amount of time as set out per application. Renewal will only be possible by way of competitive reapplication.
8.4 The funding year will commence and terminate as per contract.
8.5 Regardless of the budget details for the grant requested, and the bases in which the grant offered was determined, the grant will be offered as a “one line” grant without specification of distribution between salaries and consumables, unless otherwise specified. There will be no additional sums payable by the Foundation outside of this one line grant.
8.6 The grant must be spent wholly for the purposes for which it was requested and so certified by the investigators and the administering institution. In the event that the research is terminated early or completed at a lower than initially envisaged cost, the Foundation must be advised and any unspent funds returned.
8.7 Funds may not be used to cover any overhead costs levied by the administering institution.
8.8 The amounts requested will be very closely scrutinised by the Foundation to ensure that they reflect the true cost of doing the research proposed. The Foundation reserves the right to offer a grant sum that differs substantially from that requested by the applicants.
9. Grant Administration
9.1 The Foundation will make grant payments to the administering institution nominated in the successful grant applications. That institution will be held responsible for the proper administration and expenditure of the grant and for ensuring that all reports required by the Foundation are made in the correct form and on time.
9.2 There will only be one administering institution for each grant.
9.3 In the event a need arises for the administration of a grant to be transferred from one institution to another, a written request for this transfer must be made to the Foundation giving reasons for the transfer. The transfer must not be affected without written agreement of the Foundation.
9.4 Funds may be transferred by the administering institution to other institutions involved in the research without reference to the Foundation
10. Conduct of Research
10.1 The principal investigators are required to ensure that the research is at all times carried out in accordance with good scientific practice as per relevant Australian and international regulations.
11.1 Grant-supported personnel will be employees of the institution in which the research is done and will be subject to the conditions of employment of those institutions. The Foundation will make no contribution to the costs of their employment outside the grant offered.
11.2 Applicants may include in the budgets they submit to the Foundation a sum of 27.8% of salaries towards salary on-costs. The Foundation reserves the right to vary this provision during the course of a period of grant funding if the figures on which it was based change materially.
11.3 Resignation of an investigator during the tenure of a grant may result in termination of a project before expiration of the approved term of support. In such an event, the Foundation must be advised in writing regarding of what, if any arrangements will be made to complete the research for which the grant was offered and give a written report of progress to that date. The Foundation will decide, on the basis of the information supplied and following what other investigations it deems necessary, whether the grant should be continued in full, at a reduced level, or not at all.
12.1 A payment schedule for each grant will be agreed upon after award of grant. The first payment of a new grant will not be made until all the relevant documentation has been received by the Foundation, including authorisation for recipient created tax invoices, the signed contract and a copy of ethics approval.
12.2 The administering institution will submit an income and expenditure statement in respect of each grant-supported for each calendar year of the grant as soon as possible after 31 December, but no later than 28 February in the following year. Such a statement must certify that the grant has been expended solely for work on the program described in the application. Separate statements should be submitted for each Foundation grant administered by the institution. Reporting will be completed through Cure Brain Cancer’s online grant portal.
12.3 Failure to submit these reports will incur a financial consequence. Following a grace period of five working days after 28 February, 1% of the grant amount for the following financial year will be deducted per week when Annual Progress Reports and Statements of Income and Expenditure are not submitted.
12.4 Continuation of funding is dependent on timely receipt of satisfactory income and expenditure statements and progress reports.
12.5 At the completion of the grant period, all funds unexpended must be repaid to the Foundation unless permission is sought and obtained in writing to use any residual funds to complete work specified in the original application.
12.6 The Foundation may, at its discretion, decide to terminate a grant under any circumstances specified in this policy and conditions, or if any condition stated herein or agreed to at the time of acceptance of an offer of award is breached by any Investigator or the administering institution.
13.1 Any organisation or institution that receives a grant from the Foundation will undertake to meet from other than the grant funds all infrastructure costs pertaining to the work supported by the grant.
14. Reports, Publications and Publicity
14.1 The Principle Investigator(s) must submit a progress report on the research supported by a grant at the end of each calendar year of the grant as soon as possible after 31 December, but not later than 28 February in the following year. A set of Key Performance Indicators will be set by the successful applicant and the Foundation within the first three months of the funding period.
14.2 All publications arising from research carried out with the support of a Foundation grant must acknowledge this support in the manner specified by the Foundation. Two copies of each such publication must be supplied to the Foundation with each progress report.
14.3 The Foundation’s support must similarly be acknowledged when details of the research are released to the media. Researchers should notify the Foundation before any media release or statement, and the Foundation reserves the right to participate in formulation of the release and its communication to the media.
14.4 The Foundation may require in the above acknowledgements not only the support of the Foundation but also the specific fund or bequest from which the support has come.
14.5 The Foundation may also, at its own initiative, ask investigators to participate in release of details of their research to the media. Sensitivities relating to pre-publication release will be respected in such requests.
14.6 In more general terms, the Foundation expects researchers and institutions, to assist the Foundation, within reason, in its goal of raising funds for research and promoting awareness of the Foundation role in research.
15.1 Evidence of final ethics clearances is not required at the time of application, however it will be required before the project is to commence and prior to research funds being released. A brief statement of the ethics issues that arise from such experimentation, and an explanation of how these issues will be addressed, must be given. It is not sufficient to note that ‘the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes/NHMRC Statement on Ethical Conduct in Human Research will be observed’.
16. Intellectual Property Rights
16.1 Any intellectual property developed during the course of conducting the research supported by the Foundation under this agreement (Project IP) shall be owned by the Administering Institution.
16.2 The Administering Institution must comply with the National Principles of Intellectual Property Management for Publicly Funded Research by having in place policies and procedures relating to identification and, where appropriate, protection and commercialisation of intellectual property.
16.3 Additional intellectual property arrangements may apply depending on the specific grant scheme.
17. Contact with Cure Brain Cancer Foundation
Intending proponents are encouraged to contact Cure Brain Cancer Foundation with any questions or requests for clarification.
Contact for enquiries: